echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 2 billion injections are first declared Qilu's 35th product review.

    2 billion injections are first declared Qilu's 35th product review.

    • Last Update: 2020-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Drug Intelligence Network . . . As of July 17, CDE consistency evaluation acceptance number reached 2218, involving 584 enterprises 527 varieties (according to supplementary applications, the same below);
    the details of the evaluation of 5 varieties, Qilu, Cornbey and the first heavy productthis this week has 5 varieties through consistency evaluation, of which three varieties for the first pass, respectively, Tianshi Liyi's Shubili tablets, Qilu Pharmaceutical's single nitric acid iso-sander slow release tablets, KangEnbei's sodium sodium intestinal tablets.
    this week's consistency evaluation of the details of the table Shubili tablets Shubili tablets are benzodiazepines antipsychotic drugs, used in schizophrenia simple, paranoid, tense, and chronic schizophrenia autism, retreat, indifference symptoms.
    have some effect on depressive symptoms.
    Shubili tablets were developed by Delagrange in 1957 (now Sanofi) and are now widely sold in Europe, Japan, Russia and other countries.
    according to drug data, the current Shubili tablets for the national Class A medical insurance drugs, there are 106 domestic market approvals, involving 82 manufacturers, of which only Tianshi Liyi and Enhua Pharmaceuticals two enterprises declared consistency evaluation was accepted, now Tianshi Liyi first through the consistency evaluation, improve drug quality and competitive strength.
    mononitrate isosorate slow release tablet mononitrate sorcerer slow release tablets can prevent and long-term treatment of angina;
    according to public data show that the variety in 2019 In China's public medical institutions in the end-use of heart disease treatment products TOP20 ranked third, sales of more than 700 million yuan, of which Lunanbet pharmaceutical market share of nearly 60%.
    the current domestic single nitric acid hexalyse slow release tablets have 20 market approvals, involving 17 enterprises, of which 3 enterprises declared consistency evaluation was accepted, Qilu Pharmaceutical first passed.
    it is worth mentioning that there are currently 35 drugs approved/considered by Qilu Pharmaceuticals through consistency evaluation, which is currently the largest number of pharmaceutical stakes through consistency evaluation.
    in addition, Qilu and its subsidiaries 46 acceptance number 26 varieties of consistency evaluation supplementary applications are under review.
    Qilu Pharmaceutical consistency evaluation of the overview of the Rifuping capsule Lifupin capsules are mainly applicable to various types of sensitive tuberculosis, asymptomatic meningitis Nether carrier bacteria, sensitive non-TB mycobacteria infection and other treatment.
    China's existing domestic Lifuping capsule market approval 538, 449 manufacturers, of which Shenyang Red Flag, Hangzhou Minsheng Pharmaceuticals, Jiangsu Yuexing Pharmaceutical s3 enterprises declared consistency evaluation was accepted, of which Shenyang Red Flag was the first evaluation last year, is now Hangzhou Minsheng Pharmaceutical sapratly second review, Jiangsu Yuexing Pharmaceuticals has completed the BE test, the evaluation is also available.
    According to the data consistency evaluation progress database statistics, so far Hangzhou Minsheng Pharmaceutical industry has accumulated 8 varieties of declaration consistency evaluation of 5 of them have passed, welcome.
    the treatment of duodenal ulcers, stomach ulcers and moderate and severe reflux esophagitis, which is used to eradicate Helicobacter pylori infection in combination with kramycin and metformin (or kramycin and methazine) to reduce the recurrence of duodenum ulcers caused by this microbial infection.
    Cornbey Enterprise Announcement, the corresponding retail and medical end market for the corresponding retail and medical end-market, sales of oral preparations of protoprazole in 2019 are approximately 2.5 billion yuan.
    according to the pharmaceutical pharmaceutical sales database statistics, in 2019, the domestic sample hospital sales of sodium sodium sodium sodium intestinal tablets sales of 66.9772 million yuan, of which Shenyang Dongyu Pharmaceutical stakes up to 43.64 percent, followed by Shandong Luoxin Pharmaceuticals and Jinzhou Kutai Pharmaceuticals accounted for 25.44 percent, 16.34 percent, and Hangzhou Kangenbei did not account for the first in 10 years of the top, the first to attack the market.
    the second-generation sulfonyl pyrethroids of gliditin tablets.
    first listed in the United States in 1984 and sold by Pfizer, a product called GLUCOTROL.
    57 domestic enterprises have nearly 60 numbers of Glioquine tablets, there are two specifications of 2.5mg and 5mg.
    at present only Great Medicine and Hainan Zangang Pharmaceuticals through consistency evaluation.
    review and approval of 13 varieties through the name, phenyl sulfonate ammonia chlorate tablet30 evaluation enterprises born this week there are 14 acceptance number 13 drug approval completed, showing "approval completed - pending certification" status, details as follows: this week's consistency evaluation review review details of the popular varieties of phenyl sulfonate ammonia chlorine tablets 30 over-evaluation enterprises will be born; Mitt tablets, Kaifeng Pharmaceuticals' lipoic acid injection, Zhejiang Jing new drug industry's pivastatin calcium dispersion tablets no enterprise through unanimous evaluation, once successfully approved, will achieve the first;
    declaration accepted 10 varieties were hosted, this super 2 billion varieties of the first declaration this week CDE new consistency evaluation acceptance number 16 (10 varieties), 7 for injection, of which Zhejiang Beisheng Pharmaceuticals' Zuo Kanitin injection for the first declaration of consistency evaluation varieties, Klinmycin phosphate injections more Jiangxi Nanhai Xin Pharmaceuticals and Chengdu Push Pharmaceuticals two enterprises rushed to report.
    this week's consistency evaluation declaration accepted details of the left kanantitin injection 2019 National Health Insurance Class B catalog variety, used in chronic renal failure of long-term hemorrhoid patients due to secondary carnitine deficiency caused by a series of complications.
    public data show that in 2019 China's public medical institutions terminal sales of more than 2.158 billion yuan.
    domestic sample hospital sales reached 383 million yuan in 2019, of which Changzhou Lanling Pharmaceutical accounted for 81.37 percent of the market.
    according to the pharmaceutical wisdom domestic database statistics, the current left Kanitin injection only 12 enterprises have 12 market approval, is now Zhejiang Beisheng Pharmaceutical simply preempted Changzhou Lanling pharmaceutical declaration consistency evaluation was accepted, more than 2 billion market will be reshuffled? Wait and see how it changes.
    data source: drug intelligence data, corporate announcements and other network public data.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.